{"title":"Depression and Associated Factors among Type 2 Diabetics in Karbala City, Iraq: As a Model of Anti-depressant Drugs","authors":"TiSammar J Mahanrth, Mohammed M Mahammad","doi":"10.25258/ijddt.13.3.55","DOIUrl":null,"url":null,"abstract":"depression symptoms are well-known co-occurring diseases. A person’s ability to do everyday things can be affected by depressed symptoms and DM. Objectives: To find the level of depression symptoms among type 2 diabetics, observe the socio-demographic & disease-related agents that cause depression. Methods: A cross-sectional study design was used to assess depression in 200 people suffering from type 2 diabetes and 120 healthy participants as a control group. Patients scoring 5 or more were termed depressed. Each participant’s verbal informed consent was obtained before the interview. On the questionnaires, no names were written. Depression was correlated with demographic and patient-related disease characteristics using Spearman’s rho correlation. Results: The severe, moderate, and mild depression rates were 7.5, 56, and 29%, respectively and 92.5% of diabetics had depressed symptoms. Among the control group, absences of depressed symptoms and mild depressed symptoms were more common. Diabetics had moderate, moderately severe, and severe depression are all more common than mild depression symptoms. Diabetic patients’ median PHQ-9 score (10) was significantly higher than the control group’s 8. Conclusion: Depression is common among diabetes mellitus type 2 patients. Glycemic control is poor & obesity have an impact on it. Endocrinologists should be aware of the elevated risk of depression in this patient population","PeriodicalId":13851,"journal":{"name":"International Journal of Drug Delivery Technology","volume":"11 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Drug Delivery Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25258/ijddt.13.3.55","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0
Abstract
depression symptoms are well-known co-occurring diseases. A person’s ability to do everyday things can be affected by depressed symptoms and DM. Objectives: To find the level of depression symptoms among type 2 diabetics, observe the socio-demographic & disease-related agents that cause depression. Methods: A cross-sectional study design was used to assess depression in 200 people suffering from type 2 diabetes and 120 healthy participants as a control group. Patients scoring 5 or more were termed depressed. Each participant’s verbal informed consent was obtained before the interview. On the questionnaires, no names were written. Depression was correlated with demographic and patient-related disease characteristics using Spearman’s rho correlation. Results: The severe, moderate, and mild depression rates were 7.5, 56, and 29%, respectively and 92.5% of diabetics had depressed symptoms. Among the control group, absences of depressed symptoms and mild depressed symptoms were more common. Diabetics had moderate, moderately severe, and severe depression are all more common than mild depression symptoms. Diabetic patients’ median PHQ-9 score (10) was significantly higher than the control group’s 8. Conclusion: Depression is common among diabetes mellitus type 2 patients. Glycemic control is poor & obesity have an impact on it. Endocrinologists should be aware of the elevated risk of depression in this patient population
期刊介绍:
International Journal of Drug Delivery Technology (IJDDT) provides the forum for reporting innovations, production methods, technologies, initiatives and the application of scientific knowledge to the aspects of pharmaceutics, including controlled drug release systems, drug targeting etc. in the form of expert forums, reviews, full research papers, and short communications.